Neuropathologic effects of chemical warfare agents

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter highlights underlying mechanisms that may mediate their effects in nervous tissues. Common nerve agents developed for chemical warfare purposes include the G-series and V-series (a designation of more ambiguous origin) weapons. The G-series includes tabun (GA), sarin (GB), soman (GD), and cyclosarin (GF); the V-series includes VX, first synthesized by the British in 1954, which is approximately an order of magnitude more potent than agents of the G-series. The neuropathologic effects of chemical warfare agents, particularly OP nerve agents, have been characterized and related to a variety of central and peripheral clinical syndromes. The most prominent of these are neuronal losses at characteristic sites in cerebrum that follow and correlate with the presence of nerve agent-induced seizure activity, with accompanying glial reaction and a subsequent, incomplete neuroregenerative response. Recent progress in the understanding of excitotoxic, neuroinflammatory, and oxidative processes that may contribute to the development of neurotoxicity provides a conceptual link to other neurologic diseases. Therapies that prove successful in preventing or treating these diseases might also be translated into neuroprotective strategies that might be useful in populations exposed to chemical warfare agents.

Original languageEnglish (US)
Title of host publicationHandbook of Toxicology of Chemical Warfare Agents
PublisherElsevier Inc.
Pages653-663
Number of pages11
ISBN (Print)9780123744845
DOIs
StatePublished - Dec 1 2009

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Neuropathologic effects of chemical warfare agents'. Together they form a unique fingerprint.

  • Cite this

    Woltjer, R. L. (2009). Neuropathologic effects of chemical warfare agents. In Handbook of Toxicology of Chemical Warfare Agents (pp. 653-663). Elsevier Inc.. https://doi.org/10.1016/B978-012374484-5.00043-2